Compare INAB & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INAB | VVOS |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 15.1M |
| IPO Year | 2020 | 2020 |
| Metric | INAB | VVOS |
|---|---|---|
| Price | $1.38 | $1.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $6.25 |
| AVG Volume (30 Days) | 70.9K | ★ 160.2K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.07 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $15,031,000.00 |
| Revenue This Year | N/A | $31.42 |
| Revenue Next Year | N/A | $49.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.91 |
| 52 Week Low | $0.12 | $1.09 |
| 52 Week High | $4.20 | $7.40 |
| Indicator | INAB | VVOS |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 59.93 |
| Support Level | $1.35 | $1.44 |
| Resistance Level | $2.14 | $1.48 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 33.33 | 79.12 |
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.